Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. (Record no. 25932682)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01916 a2200541 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517091815.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201702s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1432-0843 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/s00280-016-3000-3 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Said, Rabih |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20170206 |
| 245 00 - TITLE STATEMENT | |
| Title | Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Cancer chemotherapy and pharmacology |
| Date of publication, distribution, etc. | 05 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1097-102 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Administration, Oral |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bevacizumab |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Colorectal Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease-Free Survival |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Dose-Response Relationship, Drug |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Administration Schedule |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Injections, Intravenous |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lenalidomide |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Maximum Tolerated Dose |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Melanoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Response Evaluation Criteria in Solid Tumors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Thalidomide |
| General subdivision | administration & dosage |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kakadiaris, Eugenia |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Piha-Paul, Sarina |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fu, Siqing |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Falchook, Gerald |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Janku, Filip |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wheler, Jennifer J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zinner, Ralph |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hong, David S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kurzrock, Razelle |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tsimberidou, Apostolia M |
| 773 0# - HOST ITEM ENTRY | |
| Title | Cancer chemotherapy and pharmacology |
| Related parts | vol. 77 |
| -- | no. 5 |
| -- | p. 1097-102 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1007/s00280-016-3000-3">https://doi.org/10.1007/s00280-016-3000-3</a> |
| Public note | Available from publisher's website |
No items available.